PTC Therapeutics (PTCT) announced that the U.S. FDA has approved Sephience for the treatment of children and adults living with phenylketonuria. The approval includes broad labeling for the treatment of hyperphenylalaninemia in adult and pediatric patients 1 month of age and older with sepiapterin-responsive PKU.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics trading halted, news pending
- Citi ups PTC Therapeutics target, adds ‘upside catalyst watch’
- Cautious Outlook on PTC Therapeutics: Sepiapterin’s Limited Potential to Offset Declining DMD Revenues
- PTC Therapeutics Advances Long-Term Study on Vatiquinone for Friedreich Ataxia
- PTC Therapeutics’ Gene Therapy Trial: A Promising Update for Investors